© 2015 by the authors; licensee MDPI, Basel, Switzerland. T-cells genetically redirected with a chimeric antigen receptor (CAR) to recognize tumor antigens and kill tumor cells have been infused in several phase 1 clinical trials with success. Due to safety concerns related to on-target/off-tumor effects or cytokine release syndrome, however, strategies to prevent or abat e serious adverse events are required. Pharmacologic therapies; suicide genes; or novel strategies to limit the cytotoxic effect only to malignant cells are under active investigations. In this review, we summarize results and toxicities of investigations employing CAR redirected T-cells, with a focus on published strategies to grant safety of this promising cellular application.
Minagawa, K., Zhou, X., Mineishi, S., & Di Stasi, A. (2015, May 8). Seatbelts in CAR therapy: How safe are CARS? Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph8020230